Jeena Sikho Lifecare Reports Strong FY26 Results with 178% Profit Growth

Jeena Sikho Lifecare's net profit for FY26 jumped 178.93% to ₹222.18 crore from ₹79.94 crore in FY25. Revenue grew 70.84% to ₹801.35 crore.

Reader Takeaway: Strong profit growth and dividend announcement are positive; monitor regulatory costs and acquisition approvals.

What just happened

Jeena Sikho Lifecare announced its financial results for the fiscal year ended March 31, 2026. The company posted a significant increase in both revenue and net profit. Revenue from operations grew by 70.84% to ₹801.35 crore, up from ₹469.07 crore in the previous fiscal year.

Net profit saw a substantial surge of 177.93%, reaching ₹222.18 crore compared to ₹79.94 crore in FY25. This indicates improved profitability and operational efficiency, with profit growth outpacing revenue growth.

Why this matters

The strong financial performance is a positive signal for investors, showcasing the company's ability to grow its top and bottom lines significantly. The recommended final dividend of ₹4.50 per equity share offers a direct return to shareholders, reflecting confidence in future earnings.

Furthermore, the incorporation of a new subsidiary in the UAE and a strategic investment in Chandan Healthcare Limited suggest a forward-looking approach towards expansion and diversification.

The backstory

For the financial year ended March 31, 2025, Jeena Sikho Lifecare had reported revenue of ₹469.07 crore and a net profit of ₹79.94 crore. The current fiscal year's results show a marked acceleration in growth.

What changes now

Shareholders will be looking forward to the Annual General Meeting to approve the proposed dividend. The company's strategic moves, including the new subsidiary and investment, are expected to shape its future growth trajectory.

Concerns and watch points

Investors should be aware of the impact of new labour codes, which resulted in an incremental expense of ₹1.25 crore for the company. Additionally, the transfer of a 51% stake in Back to Roots Ayurveda (UAE) is pending regulatory approvals in Abu Dhabi, which requires monitoring.

Peer comparison

While specific peer data for the exact reporting period isn't provided in the filing, the company's growth in revenue and profit can be benchmarked against other companies in the healthcare and lifecare sectors in India.

Context metrics

• Revenue (FY26): ₹801.35 crore (vs ₹469.07 crore in FY25)
• Net Profit (FY26): ₹222.18 crore (vs ₹79.94 crore in FY25)
• Dividend Recommendation: ₹4.50 per equity share
• New Subsidiary: Jeena Sikho International LLC (UAE), incorporated Sept 11, 2025
• Strategic Investment: 18 lakh share warrants in Chandan Healthcare Limited
• Regulatory Cost Impact: ₹1.25 crore due to new Labour Codes

What to track next

Investors should monitor the upcoming Annual General Meeting for dividend approval, progress on the acquisition of Back to Roots Ayurveda, and the performance of the new UAE subsidiary and Chandan Healthcare investment.